Duke Granted Expanded Access in Autism and Cerebral Palsy Trials
Duke University Medical Center received permission to expand access to cord blood therapies for brain disorders including autism and cerebral palsy. The clinical trial is open to children who have their own cord blood stored or access to partially or fully matching cord blood from a sibling.
The Food and Drug Administration (FDA) granted additional access to this clinical trial because of the promising results seen in clinical trials using both autologous and allogeneic umbilical cord blood in the treatment of cerebral palsy and autism spectrum disorder.
Duke recently released its findings from its phase II clinical trial on the safety and efficacy of treating cerebral palsy in children through an infusion of their own umbilical cord blood. Last year, it showed us some of what it saw from its phase I trial using cord blood to treat autism. This included a story on CNN of one young autistic girl who saw "supercharged" treatment results.
To further meet needs, Duke and the Cord Blood Association hope to expand the number of centers available to administer the required protocols.
Parents who have cord blood stored with Cryo-Cell and want to learn more about gaining access can use the link below to make contact with us.